Vet practice team takes on gruelling challenge to raise money for charity
STAFF members of a veterinary practice are taking on the Yorkshire Three Peaks challenge in celebration of their 25th anniversary.
15 colleagues from Ashlands Veterinary Centre, which has branches in Skipton, Glusburn and Ilkley, will be aiming to climb Penyghent, Whernside and Ingleborough, on June 12.
And while most will be walking and aiming to finish in 12 hours, vets Amy Sansby and Elizabeth Pratt and veterinary nurse Steph Ellis will run the 25 miles, including the 5,200 ascent.
The team is hoping to raise £2,500 to split between the Keighley, Craven and Upper Wharfedale branch of the RSPCA and the Veterinary Benevolent Fund (Vetlife), which gives independent, confidential and free advice to people in the veterinary community.
Ben Ogden, veterinary practice manager, said: 'This is a very special year for us as we are celebrating our 25th anniversary and we will also be opening our new hospital later in 2025, so we wanted to do a big event to mark the occasion.
'Doing the Yorkshire Three Peaks Challenge will be a great team bonding opportunity, as well as a chance to have some fun and raise money for two important charities that do so much good work for both animals and members of the veterinary community.
'Even colleagues who aren't taking part have volunteered to be support crew and we will have the practice ambulance parked are various points so we can refuel and have a rest. Some of the team are a little apprehensive but we'll be supporting each other as we always do, and it will be a great achievement.'
Excitement is building over the opening of the new hospital which will be twice the size of its current practice in Ilkley and will boast the latest equipment and technology.
Plans for the site, which is just further along Leeds Road from the existing practice, include five consulting rooms, with one dedicated to cats, three operating theatres including a dedicated dental suite, an ultra-sound suite and x-ray facilities.
The site will also house a CT scanner suite boosting the practice's capability for handling a wider variety of cases, such as orthopaedics, soft tissue issues and tumour analysis.
Investment for the practice is being provided by VetPartners, a York-based veterinary group led by members of the veterinary profession, which owns some of the UK's most respected and trusted small animal, equine, mixed and farm practices, including Ashlands Vets.
To donate to their JustGiving page, go to: https://www.justgiving.com/team/ashlandsvets?utm_medium=TE&utm_source=CL or, if you're visiting Ashlands Vets, you can donate through QR codes around the practice
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers include new pipeline products and psychedelic therapeutics. Discover market insights, competitor analysis, and strategic opportunities in the 7MM market. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for Scope Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management. Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled. Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Company Coverage: GSK Eli Lilly and Co Otsuka Pharmaceutical Co Ltd Pfizer Seelos Therapeutics Ananda Scientific Lykos Therapeutics Idorsia Pharmaceutical Compass Pathways Transcend Therapeutics Neuphoria Therapeutics Key Topics Covered: 1. Preface2. Executive Summary3. Disease Overview3.1. Overview of PTSD3.2. Pathophysiology of PTSD3.3. Classification of PTSD3.4. PTSD SWOT Analysis4. Epidemiology4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ? 18 Years, 2024?344.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 20244.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ?18 Years, 20244.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ?18 Years, 20244.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status4.8. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD4.9. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD by Disease Status5. Current Treatment Options5.1. Treatment Paradigm5.2. Current Treatment Options5.3. Product Profile: Pfizer's Zoloft/Besitran/Lustral (sertraline)5.4. Product Profile: GSK's Paxil/Deroxat/Seroxat/Aropax (paroxetine)5.5. Product Profile: Eli Lilly's Prozac (fluoxetine)5.6. Product Profile: Pfizer's Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)5.7. Product Profile: Pfizer's Minipress/Hypovase (prazosin)5.8. Patient Flow: PTSD in 2024 Across 7MM6. Unmet Needs and Opportunities6.1. Unmet Needs in PTSD6.2. New Therapeutic Options with Improved Efficacy6.3. Increase Access to Psychotherapy6.4. Treatment Options with Improved Side-Effect Profiles6.5. More consistent diagnostic and treatment guidelines7. R&D Strategies7.1. Trends in Clinical Trial Design in PTSD7.2. Regulatory Challenges for Psychedelic Treatments7.3. Timeline of Regulatory Challenges for Lykos Therapeutics7.4. Trends in Deal-Making in PTSD8. Pipeline Assessment8.1. PTSD Pipeline Overview8.2. Late-Stage Pipeline Agents for PTSD8.3. Product Profile: Otsuka Pharmaceutical's Rexulti (brexpiprazole)8.4. Product Profile: Neuphoria Therapeutics' BNC-2108.5. Product Profile: Idorsia Pharmaceutical's Quviviq (daridorexant)8.6. Product Profile: Ananda Scientific's Nantheia ATL5 (cannabidiol)8.7. Product Profile: Transcend Therapeutics' TSND-201 (methylone)8.8. Product Profile: Lykos Therapeutics' midomafetamine hydrochloride8.9. Product Profile: Seelos Therapeutics' Ereska (ketamine hydrochloride)8.10. Product Profile: Compass Pathways' COMP360 (psilocybin)8.11. PTSD: Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. PTSD Market Forecast9.2. Market Drivers and BarriersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
an hour ago
- The Hill
More cucumber products recalled as salmonella outbreak expands
(NEXSTAR) — Additional cucumber products have been recalled over concerns of potential salmonella contamination as a multistate outbreak expands. On Wednesday, Maryland-based TGD Cuts, LLC, issued a voluntary recall of sliced cucumber trays and salsa tubs over concerns that the cucumbers may be from Bedner Growers Inc. Cucumbers from the Florida-based grower have been linked to 45 cases of salmonella across 18 states, according to the Centers for Disease Control and Prevention. Unlike previous recalls, Wednesday's may not impact the items in your refrigerator. The recalled products, listed below, were distributed to retail and foodservice locations in Maryland, New Jersey, North Carolina, Pennsylvania, and Virginia, the Food and Drug Administration notice reads. The salsas and trays are beyond their shelf dates, which ranged from May 20 to May 28, 2025. According to officials, no illnesses have been reported in connection with these items. Some of the salsa was sold under the brand name of Jean's Classy. If you have any of the items listed above, you are advised to discard them immediately or return them to the store where you purchased them for a full refund. This is the latest recall related to potentially contaminated cucumbers. Last week, fresh cucumber salads and vegetable trays sold at Kroger and its affiliated stores in nine states were recalled. Others impacted products include whole cucumbers; made-to-order subs, wraps, and paninis; fresh cut cucumbers sold at select Walmart stores in Texas; veggie and sushi products sold at Kroger, Roundy's, and Weis Market stores in 16 states; salads and salsa; and salads sold to foodservice distributors and supermarkets in eight states. It's caused by the salmonella bacteria, which the CDC estimates cause 1.35 million infections, 26,500 hospitalizations, and 420 deaths in the U.S. yearly. Salmonella infections are commonly associated with diarrhea, fever, and stomach cramps, according to the CDC. Symptoms can begin between six hours and six days after you've ingested the bacteria. Most people are able to recover without receiving treatment within four to seven days. Illnesses may be more severe for young children, the elderly, and those with weakened immune systems. Some may require medical treatment or hospitalization, the CDC explains. Infections can only be diagnosed with a laboratory test of a person's stool, body tissue, or fluids. In an update last week, the CDC said 45 people across 18 states had been infected with the strain of salmonella linked to contaminated cucumbers. That's up from 26 people across 15 states reported the week prior. Eight people, who all departed from the same locations in Florida on cruises, reported becoming sick within a week of their trip. While three traveled on the same ship, the CDC says sick people were aboard six different ships total. Those ships departed between March 30 and April 12, and illnesses were first reported on April 2. Sixteen people have required hospitalization after becoming ill, but no deaths have been reported. Patients range in age from 2 to 84 years old. Those who got sick primarily live in Georgia and Florida, comprising seven and six of the confirmed cases, respectively. CDC data shows four residents from Illinois and Ohio also fell ill, as did three people each from New York, North Carolina, Pennsylvania, and Virginia. Michigan and South Carolina each had two cases, while Alabama, California, Colorado, Indiana, Kansas, Kentucky, Massachusetts, and Tennessee have all reported a single case. The CDC notes the true number of sick people connected to this outbreak may be higher, as some people are able to recover from a salmonella infection without seeking medical care. Additionally, it can take three to four weeks to determine that someone who is sick is connected to the outbreak.
Yahoo
2 hours ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
